AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

PIN Pharma to Present a Poster at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO)

May 6, 2019

NEW YORK--(BUSINESS WIRE)--May 6, 2019--PIN Pharma, a company focused on modulating the immune system and having its first indication in oncology, today announced the Company will be presenting a poster at the 55th Annual meeting of ASCO in Chicago on June 1 between 8:00 AM – 11:00 reporting the results of the first-in-human trial evaluating the immune activation and safety of PIN-2 administered to patients with advanced solid tumors.

About PIN-2

PIN-2 is a novel immunomodulatory peptide with a unique mechanism of action in that it links the innate and adaptive immune systems, resulting in an enhanced immune response. In vitro and in vivo preclinical studies have shown that PIN-2 rapidly and preferentially penetrates monocytes, modifies the mRNAs involved in the induction of innate immune activation (with an attendant link to the adaptive immune system), and promotes endogenous cytotoxic T lymphocytes infiltration at the tumor site. PIN-2 acts upstream of other immune-based treatment modalities.

Given its unique, upstream immunomodulatory activity, its extensive preclinical body of evidence, and its first-in-human study results, PIN-2 holds the potential to be a new strategy in the fight against cancer and cancer-mediated immunosuppression. Further clinical research is warranted to evaluate the full potential of PIN-2 in cancer care.

About PIN Pharma, Inc.

PIN Pharma is a clinical stage, biopharmaceutical company dedicated to the development of PINs (precision immune stimulants)—immunomodulatory peptides that link the innate and adaptive immune systems to enhance the body’s ability to fight cancer. Although the company is currently focusing on immune oncology, PINs have potential application in other therapeutic areas involving the immune system.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190506005101/en/

CONTACT: Colin Bier, PhD, CEO (cbier@pinpharma.com)

Mark Smith, CFO (msmith@pinpharma.com)

PIN Pharma, Inc.

55 Broadway, Suite 317,

New York, NY 10006

Phone: 212-543-2583

KEYWORD: UNITED STATES NORTH AMERICA NEW YORK

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL RESEARCH SCIENCE GENERAL HEALTH

SOURCE: PIN Pharma, Inc.

Copyright Business Wire 2019.

PUB: 05/06/2019 09:00 AM/DISC: 05/06/2019 09:01 AM

http://www.businesswire.com/news/home/20190506005101/en

All contents © copyright 2019 The Associated Press.All rights reserved.